Myriad Genetics

Myriad Genetics, Inc.
Company type	Public
Traded as	Nasdaq: MYGN; S&P 600 Component
Industry	Healthcare; Molecular Diagnostics; Biotechnology; Precision Medicine
Founded	1991, in Salt Lake City, Utah, United States
Founder	Mark SkolnickKevin Kimberlin
Headquarters	Salt Lake City, Utah
Key people	Paul J. Diaz (president and CEO); Jerry Lanchbury (CSO); Walter Gilbert (director and vice chair)
Revenue	$690.6 Million(2021)
Number of employees	2,600
Website	myriad.com

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy (precision medicine), assess a patient's risk of disease progression and disease recurrence (precision medicine), and measure disease activity.

[1] "Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives". 24 February 2021.

[2] "Myriad's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile".

[1]

[2]